Abstract
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with glucocorticoids and there are no approved steroid-sparing medications. There is emerging evidence that Janus kinase (JAK) inhibitors, which inhibit JAK-dependent cytokine activity, may hold promise in sarcoidosis. In this open-label trial, 10 patients with recalcitrant sarcoidosis with cutaneous involvement were treated with tofacitinib 5 mg twice daily. There was no washout period and patients were permitted to continue, taper, or discontinue other treatments. The primary outcome was the change in the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI) activity score after 6 months. Change in internal organ disease activity was also assessed using total lesion glycolysis (TLG) determined by full-body positron emission tomography. A mean reduction in the CSAMI activity score of 82.7% was observed, with 6 patients showing a complete response. Internal organ response data was available in 8 patients; a decrease in TLG of ≥50% was noted in 5 patients, with complete or near complete resolution in 3 (>98% reduction in TLG). Patients were generally able to significantly taper or discontinue their baseline immunosuppressive regimen, which included prednisone in 5 patients. Single cell RNA-sequencing, bulk RNA-sequencing, and high-throughput proteomic analyses were performed on skin and blood as a function of treatment in order to delineate changes in immunologic signals with therapy. We identified CD4+ T cell derived IFN-γ as a central cytokine driver of sarcoidosis and inhibition of its activity was achieved with tofacitinib and correlated closely with clinical improvement. Tofacitinib appears to have impressive activity in treatment of sarcoidosis and likely acts by inhibiting IFN-γ, larger, controlled studies are warranted.
Competing Interest Statement
WD has research funding from Pfizer, serves as a consultant for Eli Lilly Pfizer and Twi Biotechnology and receives licensing fees from EMD/Millipore/Sigma. BDY receives research funding from Pfizer. EJM receives research funding from Alnylam Pfizer and Eidos and serves as a consultant for Alnylam Pfizer and Eidos. MB is a consultant for Eli Lilly and receives licensing fees from EMD/Millipore/Sigma. RAF is a consultant for Glaxo Smith Kline and Zai labs. BK is a consultant to and/or has served on advisory boards for Aclaris Therapeutics Arena Pharmaceuticals Bristol-Meyers Squibb Concert Pharmaceuticals Inc Dermavant Sciences Eli Lilly and Company Pfizer and VielaBio. He is on speakers bureau for Pfizer Regeneron and Sanofi Genzyme. AW RA CR MKM RFC DP and MG have no disclosures.
Clinical Trial
NCT03910543
Funding Statement
Funded by Pfizer via an investigator-initiated research proposal (W.D.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Yale IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: WD has research funding from Pfizer, serves as a consultant for Eli Lilly, Pfizer, and Twi Biotechnology, and receives licensing fees from EMD/Millipore/Sigma. BDY receives research funding from Pfizer. EJM receives research funding from Alnylam, Pfizer, and Eidos and serves as a consultant for Alnylam, Pfizer, and Eidos. MB is a consultant for Eli Lilly and receives licensing fees from EMD/Millipore//Sigma. RAF is a consultant for Glaxo Smith Kline and Zai labs. BK is a consultant to and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, Pfizer, and VielaBio; he is on speaker’s bureau for Pfizer, Regeneron and Sanofi Genzyme. AW, RA, CR, MKM, RFC, DP, and MG have no disclosures.
Funding: Funded by Pfizer via an investigator-initiated research proposal (W.D.).
Clinical Trial Registration: ClinicalTrials.gov: NCT03910543
Data Availability
scRNA-seq, bulk RNA-seq, and proteomic data have been uploaded to Gene Expression Omnibus (Accession number pending).
